TaiGen links with Zhejiang in cross-strait China deal for nemonoxacin
This article was originally published in Scrip
In a sign of the steady thawing, at least in business relations, between mainland China and Taiwan, the Hangzhou-based Zhejiang Medicine Company (ZMC) has signed a deal with TaiGen Biotechnology in Taipei for what they describe as the world's first broad-spectrum, non-fluorinated quinolone antibiotic in development for respiratory infections.
You may also be interested in...
The road to China's health-care market, once seen to be paved with gold by many medtech companies, is presenting more obstacles than before as a result of increased local competition and challenging policies. Multinationals and start-ups attending the recent China Healthcare Investment Conference discussed ways in which the medtech industry could continue to capitalize on this market's potential.
China is pushing ahead with initiatives in the precision medicine area, where it sees targeted diagnosis and treatment as particularly valuable in areas such as oncology, diabetes and cardiovascular disorders.
The China Food and Drug Administration has released the final version of its biosimilars guideline1.